To assess NILK-2301 activity and mechanism of action, we first addressed killing of CEACAM5-positive tumor cell lines co-incubated with PBMCs from healthy human donors (containing approximately 50% of CD3+ T-cells) as effector cells. This evidence concerns the gene CEACAM5 and neoplasm.